What is Larazotide?
Tight-junction regulator peptide studied for gut barrier and celiac-associated symptoms.
Research Indications
Demonstrated acceleration of wound healing and soft tissue repair in research
Research shows beneficial effects on intestinal lining and GI function
Associated with reduced joint inflammation and improved mobility
May support faster recovery from muscle strains and exercise stress
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Starting Dose | 100 mcg | Once daily | Subcutaneous injection |
| Standard Dose | 250 mcg | Once daily | Subcutaneous injection |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove Larazotide vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.
Week 2–4
Improved tissue mobility and reduced discomfort. Early healing acceleration.
Week 4–8
Significant recovery milestones. Stronger tissue repair and functional improvement.
Week 8–12
Near-complete healing in many cases. Improved strength and tissue integrity.
Side Effects & Safety
- Generally well-tolerated in research settings
- Mild nausea with higher doses
- Injection site redness or discomfort
- Rare: Dizziness or lightheadedness
- Potential effect on blood pressure (monitor if hypertensive)
FDA Status & Regulatory Info
Tight-junction regulator peptide studied for gut barrier and celiac-associated symptoms.
Frequently Asked Questions
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
What 1,343 users report
Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 47% · Mixed 34% · Unfavorable overall 19%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 0.6–1 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
How repeat users are trending
Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 295 repeat reporters
Share Your Experience
Rate Larazotide in the PeptIQ app and help the community make informed decisions.
Research References (3)
Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.
- Wiki study page →Source
PubMed
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet
Leffler DA, Kelly CP, Abdallah HZ, et al. Gastroenterology. 2015
- Wiki study page →Source
PubMed
Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration
Damianos JA, Bledsoe A, Camilleri M, et al. Gut. 2026
- Wiki study page →Source
PubMed
The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate
Khaleghi S, Ju JM, Lamba A, et al. Therapeutic advances in gastroenterology. 2016
Wiki tools
Observational indexes and compare views for Larazotide.
Often tracked with
Educational information only
This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.